VCEL

SEC source: 0001593968-22-000892 · primary_01.xml · derivative · entry 3

Wotton Paul K · CIK 0001300997 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2032-04-27

F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001593968-22-000892 · primary_01.xml · derivative · entry 2

Wotton Paul K · CIK 0001300997 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000892 · primary_01.xml · nonDerivative · entry 1

Wotton Paul K · CIK 0001300997 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,202

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 28, 2021.

SEC source: 0001593968-22-000891 · primary_01.xml · derivative · entry 4

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,600

Underlying: Common Stock · 2,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000891 · primary_01.xml · derivative · entry 3

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2032-04-27

F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001593968-22-000891 · primary_01.xml · derivative · entry 2

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000891 · primary_01.xml · nonDerivative · entry 1

GILMAN STEVEN C · CIK 0001379970 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 28, 2021.

SEC source: 0001593968-22-000890 · primary_01.xml · derivative · entry 4

MCLAUGHLIN KEVIN F · CIK 0001214938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,600

Underlying: Common Stock · 2,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000890 · primary_01.xml · derivative · entry 3

MCLAUGHLIN KEVIN F · CIK 0001214938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2032-04-27

F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001593968-22-000890 · primary_01.xml · derivative · entry 2

MCLAUGHLIN KEVIN F · CIK 0001214938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000890 · primary_01.xml · nonDerivative · entry 1

MCLAUGHLIN KEVIN F · CIK 0001214938 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 28, 2021.

SEC source: 0001593968-22-000889 · primary_01.xml · derivative · entry 4

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2032-04-27

F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001593968-22-000889 · primary_01.xml · derivative · entry 3

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,600

Underlying: Common Stock · 2,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F5 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000889 · primary_01.xml · derivative · entry 2

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000889 · primary_01.xml · nonDerivative · entry 1

Rubino Alan L · CIK 0001340228 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 28, 2021.

SEC source: 0001593968-22-000888 · primary_01.xml · derivative · entry 4

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2032-04-27

F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.

SEC source: 0001593968-22-000888 · primary_01.xml · derivative · entry 3

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,600

Underlying: Common Stock · 2,600 shares

Expires not disclosed

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F5 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000888 · primary_01.xml · derivative · entry 2

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022.

F4 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000888 · primary_01.xml · nonDerivative · entry 1

Hagen Heidi · CIK 0001585084 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,850

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 28, 2021.

SEC source: 0001127602-23-004886 · form5.xml · nonDerivative · entry 1

Flynn Sean C. · CIK 0001801993 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,660

F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001127602-23-004890 · form5.xml · nonDerivative · entry 1

Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,673

F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000613 · primary_01.xml · derivative · entry 6

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,750

Underlying: Common Stock · 10,000 shares

Expires 2030-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: These options, representing the right to purchase 48,750 shares, became exercisable in quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 11, 2020.

SEC source: 0001593968-22-000613 · primary_01.xml · derivative · entry 5

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,604

Underlying: Common Stock · 10,000 shares

Expires 2028-08-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.

SEC source: 0001593968-22-000613 · primary_01.xml · nonDerivative · entry 4

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,176

F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021.

F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000613 · primary_01.xml · nonDerivative · entry 3

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,914

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000613 · primary_01.xml · nonDerivative · entry 2

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,914

F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2021.

F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000613 · primary_01.xml · nonDerivative · entry 1

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,914

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000517 · primary_01.xml · derivative · entry 3

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 1,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000517 · primary_01.xml · nonDerivative · entry 2

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,914

F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000517 · primary_01.xml · nonDerivative · entry 1

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,644

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000516 · primary_01.xml · derivative · entry 3

Halpin Michael · CIK 0001778858 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,438

Underlying: Common Stock · 2,812 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000516 · primary_01.xml · nonDerivative · entry 2

Halpin Michael · CIK 0001778858 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,247

F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000516 · primary_01.xml · nonDerivative · entry 1

Halpin Michael · CIK 0001778858 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,495

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000515 · primary_01.xml · derivative · entry 3

Flynn Sean C. · CIK 0001801993 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,250

Underlying: Common Stock · 1,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000515 · primary_01.xml · nonDerivative · entry 2

Flynn Sean C. · CIK 0001801993 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,445

F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000515 · primary_01.xml · nonDerivative · entry 1

Flynn Sean C. · CIK 0001801993 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,314

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000514 · primary_01.xml · derivative · entry 3

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,813

Underlying: Common Stock · 8,937 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000514 · primary_01.xml · nonDerivative · entry 2

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,432

F3 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000514 · primary_01.xml · nonDerivative · entry 1

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,307

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively.

F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-22-000517 · primary_01.xml · derivative · entry 6

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,865

Underlying: Common Stock · 2,865 shares

Expires 2032-02-18

F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.

SEC source: 0001593968-22-000517 · primary_01.xml · derivative · entry 5

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,300

Underlying: Common Stock · 9,300 shares

Expires not disclosed

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000517 · primary_01.xml · derivative · entry 4

Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,385

Underlying: Common Stock · 51,385 shares

Expires 2032-02-18

F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.

SEC source: 0001593968-22-000516 · primary_01.xml · derivative · entry 6

Halpin Michael · CIK 0001778858 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,300

Underlying: Common Stock · 15,300 shares

Expires not disclosed

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000516 · primary_01.xml · derivative · entry 5

Halpin Michael · CIK 0001778858 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,385

Underlying: Common Stock · 86,385 shares

Expires 2032-02-18

F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.

SEC source: 0001593968-22-000516 · primary_01.xml · derivative · entry 4

Halpin Michael · CIK 0001778858 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,865

Underlying: Common Stock · 2,865 shares

Expires 2032-02-18

F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.

SEC source: 0001593968-22-000515 · primary_01.xml · derivative · entry 6

Flynn Sean C. · CIK 0001801993 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,865

Underlying: Common Stock · 2,865 shares

Expires 2032-02-18

F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.

SEC source: 0001593968-22-000515 · primary_01.xml · derivative · entry 5

Flynn Sean C. · CIK 0001801993 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,300

Underlying: Common Stock · 9,300 shares

Expires not disclosed

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000515 · primary_01.xml · derivative · entry 4

Flynn Sean C. · CIK 0001801993 · VP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,385

Underlying: Common Stock · 51,385 shares

Expires 2032-02-18

F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.

SEC source: 0001593968-22-000514 · primary_01.xml · derivative · entry 6

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,800

Underlying: Common Stock · 46,800 shares

Expires not disclosed

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F7 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 18, 2023. The remaining RSUs will vest in annual installments on February 18, 2024, February 18, 2025, and February 18, 2026, respectively.

F5 · derivative.expiration_date: No expiration date for this type of award.

SEC source: 0001593968-22-000514 · primary_01.xml · derivative · entry 5

Colangelo Dominick · CIK 0001313403 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,135

Underlying: Common Stock · 270,135 shares

Expires 2032-02-18

F6 · derivative.exercise_date: These options shall begin vesting on February 18, 2022 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.